Pure Global AI
NCT06357806Recruiting

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

The Safety and Efficacy of PD-1 Antibody Combined With Pegylated Interferon-α Therapy to Promote the Clinical Cure in Nucleoside (Acid) Analogues-suppressed Chronic Hepatitis B Patients: A Protocol for the Prospective Pilot Study
Beijing 302 HospitalClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Chronic Hepatitis B
Drug/Device/Intervention
Sintilimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Beijing 302 Hospital
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
Oct 30, 2025
Enrollment
45 participants
Primary outcome

The rate of HBsAg loss at 24 weeks and 48 weeks.,Incidence of treatment-emergent adverse events/serious adverse events

Summary

This is a prospective, open-labled, randomized controlled study to assess efficacy and safety
 of treatment with Sintilimab (PDL-1 antibody) combined Peg-IFNα-2b in CHB patients on stable
 NAs treatment.

ICD-10 classifications
Acute hepatitis BChronic viral hepatitis B without delta-agentAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agent : other and unspecified phaseChronic viral hepatitis B without delta-agent : immune-tolerant phase
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06357806
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06357806 through Pure Global AI's free database. This phase not specified trial is sponsored by Beijing 302 Hospital and is currently Recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 45 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.